|1|Results of docetaxel plus oxaliplatin (DOCOX) A+ cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study. (23747051)
Richards D.... Asmar L.
|2|Snail1 correlates with patient outcomes in E-cadherin-preserved gastroesophageal junction adenocarcinoma. (24356933)
Dong H.... Zhang H.
|3|Gastroesophageal junction adenocarcinoma metastasizing to gingiva. (23776844)
Masamatti S.S.... Sulhyan K.R.
|4|Reconstructive options for gastroesophageal junction adenocarcinoma after Roux-en-Y gastric bypass. (23988286)
Kulaylat A.N.... Kaifi J.T.
|5|A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma. (23921575)
Park I.... Kang Y.K.
|6|HER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma. (23946770)
Huang J.X.... Qian R.Y.
|7|Genetic polymorphisms at TIMP3 are associated with survival of adenocarcinoma of the gastroesophageal junction. (23527119)
Bashash M.... Brooks-Wilson A.
|8|The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel. (23420289)
Bar-Sela G.... Ben-Izhak O.
|9|HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. (21617522)
Kunz P.L.... Pai R.K.
|10|Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma. (21769462)
Cohen D.J.... Muggia F.
|11|Results of postoperative radiochemotherapy of the patients with resectable gastroesophageal junction adenocarcinoma in Slovenia. (23412351)
Jeromen A.... RatoA!a I.
|12|HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. (22646280)
Hechtman J.F.... Polydorides A.D.
|13|Relationship between gastroesophageal junction adenocarcinoma and Helicobacter pylori infection in Japan. (22472851)
Kamada T.... Haruma K.
|14|Clinicopathologic characteristics and survival outcomes of patients with advanced esophageal, gastroesophageal junction, and gastric adenocarcinoma: a single-institution experience. (23300355)
Dechaphunkul A.... Spratlin J.
|15|Preoperative chemotherapy with cisplatin and docetaxel followed by surgery and clip-oriented postoperative chemoradiation in patients with localized gastric or gastroesophageal junction adenocarcinoma: results from a phase II feasibility study. (21063792)
Spizzo G.... MA1hlmann G.
|16|A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. (20574790)
Shah M.A.... Kelsen D.P.
|17|Gastroesophageal junction adenocarcinoma of young patients who underwent curative surgery: a comparative analysis with older group. (21264755)
Yoon H.Y.... Kim C.B.
|18|Adjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and gastroesophageal junction adenocarcinoma. (21338186)
Uncu D.... Zengin N.
|19|Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. (20458043)
Sun W.... Benson A.B.
|20|Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma. (19267943)
Di Lauro L.... Lopez M.
|21|Array comparative genomic hybridization, expression array, and protein analysis of critical regions on chromosome arms 1q, 7q, and 8p in adenocarcinomas of the gastroesophageal junction. (19167610)
Van Dekken H.... van Marion R.
|22|Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma. (19487968)
Rizk N.P.... Rusch V.W.
|23|Transition in biology and philosophy in the treatment of gastroesophageal junction adenocarcinoma. (19139425)
Tepper J.E.... O'Neil B.
|24|Polymeric immunoglobulin receptor-negative tumors represent a more aggressive type of adenocarcinomas of distal esophagus and gastroesophageal junction. (18684029)
Gologan A.... Sepulveda A.R.
|25|Is radiation therapy needed in the treatment of gastroesophageal junction adenocarcinoma? (19343142)
|26|Molecular dissection of the chromosome band 7q21 amplicon in gastroesophageal junction adenocarcinomas identifies cyclin-dependent kinase 6 at both genomic and protein expression levels. (18438866)
Van Dekken H.... van Duin M.
|27|Anti-Yo-associated paraneoplastic cerebellar degeneration in a man with adenocarcinoma of the gastroesophageal junction. (17785986)
Debes J.D.... Van Lanschot J.J.
|28|The prevalence of Helicobacter pylori infection and the status of gastric acid secretion in patients with gastroesophageal junction adenocarcinoma in Japan. (17450443)
Koike T.... Shimosegawa T.
|29|Interleukin-1 genetic polymorphisms and their relationship to the cancer anorexia/weight loss syndrome in metastatic gastric and gastroesophageal junction adenocarcinoma. (17265786)
Jatoi A.... Nikcevich D.A.
|30|Molecular prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction. (17122988)
Lagarde S.M.... Van Lanschot J.J.
|31|New proposal for postsurgery pathologic staging of esophageal or gastroesophageal junction adenocarcinoma: why bother? (17327615)
|32|Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. (17050876)
Dragovich T.... Abbruzzese J.L.
|33|Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. (16985029)
Chak A.... Eng C.
|34|Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma. (16880795)
Falk S.... Ajani J.
|35|Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. (17114652)
Shah M.A.... Kelsen D.P.
|36|A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. (16683077)
Ajani J.A.... Bleyer A.
|37|Preservation of gastric acid secretion may be important for the development of gastroesophageal junction adenocarcinoma in Japanese people, irrespective of the H. pylori infection status. (16573782)
Inomata Y.... Shimosegawa T.
|38|Gastroesophageal junction adenocarcinoma: what are the factors influencing long-term survival? (16845860)
Del Genio A.... Di Martino M.
|39|Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. (16446338)
Ajani J.A.... Strumberg D.
|40|Reduced p120ctn expression correlates with poor survival in patients with adenocarcinoma of the gastroesophageal junction. (16231374)
Wijnhoven B.P.... Tilanus H.W.
|41|Significance and prognostic value of lysosomal enzyme activities measured in surgically operated adenocarcinomas of the gastroesophageal junction and squamous cell carcinomas of the lower third of esophagus. (16270380)
Altorjay A.... Sohar I.
|42|Comparison of the clinical and histological characteristics and survival of distal esophageal-gastroesophageal junction adenocarcinoma in patients with and without barrett mucosa. (15967904)
Portale G.... DeMeester T.R.
|43|Neuroendocrine in Barrett's mucosa and adenocarcinomas of the gastroesophageal junction. (15173916)
Koppert L.B.... Dinjens W.N.
|44|Molecular genetic analysis of the von Hippel-Lindau and human peroxisome proliferator-activated receptor gamma tumor-suppressor genes in adenocarcinomas of the gastroesophageal junction. (11745495)
Wijnhoven B.P.... Dinjens W.N.
|45|Gastroesophageal junction adenocarcinoma. (12057146)
Swisher S.G.... Ajani J.A.
|46|Comparative genomic hybridization of cancer of the gastroesophageal junction: deletion of 14Q31-32.1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas. (9973227)
Van Dekken H.... Rosenberg C.
|47|Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction. (10210540)
Safran H.... Wanebo H.
|48|A phase II study of 5-fluorouracil, leucovorin, adriamycin, and cisplatin (FLAP) for metastatic gastric and gastroesophageal junction adenocarcinoma. A Penn Cancer Clinical Trial Group and Roswell Park Cancer Institute Community Oncology Research Program Trial. (9167745)
Vaughn D.J.... Haller D.G.
|49|Rapid progression of gastroesophageal junction adenocarcinoma after liver transplantation. (9013353)
Yao F.... Hart M.
|50|Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction. (8418237)
Ajani J.A.... McMurtrey M.